Clinical Trial Update: Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura [Phase 2]

View source ↗

Summary

A Phase II trial of rituximab for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Status: COMPLETED